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Abstract The catalytic activities of recombinant cytochrome 
P45Os expressed in E. coli have been impeded by the absence of 
endogenous P450 reductase. To solve this problem, we coex- 
pressed P450 reductase with CYP3A4. Membranes from this 
strain contained 215 pmol P45O/mg protein and a reductase 
activity of 1315 nmol cytochrome c reducetimin per mg. We 
detected 6fShydroxylation of testosterone and oxidation of 
nifedipine in vivo with turnover numbers of 15.2 and 17.3 min-‘, 
respectively. These values compare favourably with those 
obtained using an optimally reconstituted system. Our data 
demonstrate that a catalytically efficient human P450 system 
can be generated in E. coli. 
Key words: Recombinant cytochrome P450, human; Drug 
metabolism; Bioreactors; Heterologous expression; E. coli 
1. Introduction 
Mammalian cytochrome P450 monooxygenases comprise a 
superfamily of membrane-bound hemoproteins that catalyse 
the metabolism of a wide variety of endogenous and exoge- 
nous compounds, including steroids, therapeutic drugs and 
carcinogens [l-3]. To be catalytically active, microsomal 
P45Os require a supply of electrons, which are provided by 
NADPH-cytochrome P450 oxidoreductase (P450 reductase; 
EC 1.6.2.4) [4]. 
The study of human cytochrome P45Os has been greatly 
facilitated by their expression in heterologous systems, includ- 
ing mammalian cells [5-71, insect cells [8], yeast [9,10] and E. 
coli [1 l-161. While E. coli expression systems have the advan- 
tages of being easier and less expensive to handle, and gen- 
erally yield higher quantities of recombinant proteins, one 
limitation is the absence of an endogenous P450 reductase, 
resulting in very low P450 enzyme activities in membranes 
derived from these expression strains [16]. For example, while 
the steroidogenic P45Oc17 has been demonstrated to couple, 
albeit inefficiently, with an endogenous NADPH-flavodoxin 
reductase in E. coli [17] the testosterone 6P-hydroxylase activ- 
ity of recombinant cytochrome P450 3A4 (CYP3A4) was 
found to be barely detectable in E. coli (the turnover number 
was 1.6 X 1 Op5 min-‘, approximately a million-fold lower than 
the activity obtained in a reconstituted system [18]). Conse- 
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quently, the catalytic parameters of recombinant mammalian 
P45Os have mainly been determined in reconstituted systems 
in which exogenous P450 reductase is supplied. Such recon- 
stituted systems can be rather complex, as some P45Os are also 
reported to require other components such as cytochrome bg, 
glutathione, detergent and a particular phospholipid composi- 
tion for maximal activity. This is exemplified by studies with 
the abundant isoform CYP3A4, which catalyses the metabo- 
lism of a large number of drugs and steroids, and the activity 
of which has been reported to be stimulated by cytochrome bs 
for metabolism of certain substrates [ 11,18,19]. 
Recently, the ethanol inducible cytochrome P450 2El 
(CYP2El) has been coexpressed with rat P450 reductase in 
E. coli [20]. The resulting bacterial membranes contained P450 
and P450 reductase, and solubilised membranes were shown 
to catalyse oxidation of p-nitrophenol and N-nitrosodimethyl- 
amine. However, no substrate oxidation could be observed in 
intact E. coli and P450 yield was low (0.8 nmol/l culture). In 
the present study, we have established a highly active P450 
monooxygenase system in E. coli cells by coexpression of 
CYP3A4 and P450 reductase. 
2. Materials and methods 
2.1. Construction of coexpressian plasmid 
The E. coli K12 strain used throughout was JM109. The vector 
pCW has previously been employed for the successful expression 
of several mammalian P45Os including CYP3A4 [ll] and was used 
here for the expression of P450 reductase and CYP3A4. The plasmid 
pJR4 comprises the pCW vector containing the human P450 re- 
ductase cDNA translationally fused to the bacterial pelB signal 
sequence. The sequence of the 5’ end of the cDNA is: 
[‘ATGAAATACCT-GCTGCCGACCGCTGCTGCTGGTCTGCTG- 
CTCCTCGCTGCCCAGCCGGCGATGGCCATGGATATCGGAT- 
CCGAATTCCGCAACATG-human P450 reductase cDNA (N 2 
kb)3’], where the pelB leader sequence is shown underlined and’ the 
native P450 reductase ATG start codon is shown in bold. NF14 @CW 
containing a CYP3A4 sequence which had been optimized for expres- 
sion in E. coli) was constructed in such a way as to be identical to that 
made by Gillam et al. [1 11. Plasmid pB215 was constructed by replac- 
ing the &II-Bg/II fragment of NF14 containing a transcription ter- 
minator with a San-Bg/II double-stranded oligonucleotide containing 
a trpA transcription terminator of the following sequence (only top 
strand shown): “‘TCGACAGCCCGCCTAATGAGCGGGCTT-IT- 
TTTTA3’, thereby removing one of the two vector-derived BgflI sites. 
A BclI-BgflI fragment from pJR4 containing the pelB-reductase 
cDNA with its expression signals was subcloned into pB215 at ‘the 
unique BgnI site to create pB216. 
2.2. Coexpression of CYP3A4 and P450 reductase in E. coli 
Expression conditions were a modification of those described else- 
where [ll]. JM109 cells were transformed with pB216 and transfor- 
mants isolated on LB agar plates containing 50 pg/ml ampicillin. 
Transformants were streaked to single colonies which were used to 
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inoculate 5 ml starter cultures in LB broth containing ampicillin, and 
were grown with shaking at 37°C overnight. Induction of expression 
was carried out in Terrific Broth modified and supplemented as de- 
scribed [ll], but also containing 0.5 mM S-aminolevulinic acid and 
inoculated with 11100 volume overnight culture. Cells were grown 
shaking at 200 rpm, 30°C until AGasnm 0.5-0.7 prior to induction 
with 1 mM IPTG. Growth and expression of the recombinant pro- 
teins was then continued for 20-24 h at 30°C with shaking at 200 
rpm. 
2.3. Harvesting cultures, membrane jkactionation and determination of 
expression levels 
Cells were harvested and resuspended in 2.5 ml 100 mM Tris-acet- 
ate (pH 7.6), 0.5 M sucrose, 0.5 mM EDTA (2XTSE) as described 
[lo]. An equal volume of ice-cold water was then added. Membrane 
fractions were isolated from the cells as described [lo]. The P450 and 
P450 reductase content of the membranes was determined. The 
CYP3A4 content was determined using Fe’+-CO vs. Fe’+ difference 
spectra by mixing 100 ul cell or membrane suspension in 1 X TSE with 
1900 ~1 100 mM Tris-Cl (pH 7.4) 10 mM CHAPS, 20% v/v glycerol, 
1 mM EDTA, and a few crystals of sodium dithionite added. The 
spectrum was recorded as described [21]. The yield of active P450 
reductase was estimated in membranes using a spectrophotometric 
assay to measure cytochrome c reductase [22]. 
2.4. Immunodetection of recombinant CYP3A4 and P450 reductase 
Immunoblotting was performed as described [23]. Primary antibod- 
ies were a mixture of rabbit anti-rat CYP3A and anti-rat P450 re- 
ductase immunoglobulins and the secondary antiserum was HRP- 
linked donkey anti-rabbit immunoglobulin. P450 reductase and 
CYP3A4 proteins were detected using enhanced chemiluminescence 
(ECL; Amersham). 
2.5. Metabolism of CYP3A4 substrates 
2.5.1. Testosterone 6P-hydroxylase assays. Assays were carried out 
with cells and membrane fractions. In both cases, approx. 100 pmol 
P450 was incubated with shaking in TSE containing 30 mM MgCls. 
The final testosterone concentration was 0.2 mM. Where membranes 
were used, an NADPH generating system was added (final concentra- 
tion 1 mM NADP, 5 mM glucose 6-phosphate, 1 unit glucose-6- 
phosphate dehydrogenase). Reactions were carried out at 37°C for 
5 min, then stopped by addition of 1 ml ice-cold methanol and placed 
on ice for 10 min. Following centrifugation, supernatants were diluted 
with an equal volume of ice-cold water, and the testosterone metabo- 
lites extracted using Isolute Cl8 columns (IST Ltd), and eluted in 1 ml 
methanol. The methanol was evaporated in a SpeedVac and the me- 
tabolites were separated by HPLC on a Spherisorb ODS-2 (5 pm) 
250 x4.6 mm column using a gradient based on water, methanol 
and acetonitrile. at a flow rate of 1 ml/min, and detected at 240 
nm. The yield of the 6B-hydroxytestosterone was calculated by refer- 
ence to a known concentration of this metabolite. The HPLC method 
was supplied by Glaxo-Wellcome, and testosterone metabolites by 
Steraloids Inc. (a gift from Sterling Winthrop). 
2.5.2. Erythromycin N-demethylase assays. Bacterial membrane 
fractions were incubated with 0.5 mM erythromycin in 50 mM 
Table 1 
Cytochrome P450 content and cytochrome c reductase activities of 
JM109 NF14 and JM109 pB216 cells and/or membranes 
P450 content Reductase activity 
nmoV1 culturea pmollmg” (nmol cyt. c reduced/min per mg) 
pCW nd. nd. 38f16 
NF14 222 + 35 350 f 50 30f3 
pJR4 nd. nd. 1355f380 
pB216 200245 215?35 1315f321 
P450 contents were measured by Fe *+-CO vs. Fe*+ difference spectra. 
Contents are expressed as means of 4 experiments f S.D. Reductase 
activities were calculated by measuring the rate of reduction of cyto- 
chrome c per mg protein in membrane fractions, and values are given 
as means of four experiments + S.D. nd., no detectable activity. 
“Content was measured in 50 ~1 cells in 1 x TSE (N 0.5 ml culture). 
“Content was assessed per mg protein in membrane fractions derived 
from recombinant bacteria. 
HEPES buffer (pH 7.5) containing 150 mM KC1 and 10 mM MgCls 
in the presence of NADPH generating system (as above), for 20 min 
at 37°C. The formation of formaldehyde was detected using the Nash 
reagent [24,25]. 
2.5.3. Nifedipine oxidase assays. Cells or membrane fractions were 
incubated with 0.2 mM nifedipine in TSE containing 30 mM MgCla 
at 37°C for 10 min with shaking. Where membrane fractions were 
used, NADPH generating system was included (as above). The reac- 
tions were stopped by adding ice-cold methanol (30% v/v final con- 
centration) and perchloric acid (1.5% v/v final concentration) and the 
precipitated protein collected by centrifugation. The supernatants 
were transferred to HPLC vials and nifedipine and its oxidised me- 
tabolite were separated isocratically on a Spherisorb ODS-2 (5 pm) 
250x4.6 mm column using a mobile phase of methanol, acetonitrile 
and water (25:30:45 v/v), and detected at 254 nm by HPLC. The 
amount of product formed was calculated by reference to a standard 
containing a known concentration of oxidised nifedipine. 
3. Results 
3.1. Construction of a plasmid for coexpression of CYP3A4 
and P450 reductase 
Preliminary experiments to optimise expression of P450 re- 
ductase in E. coli indicated that high levels of IPTG-inducible 
expression were achieved from pJR4. In this construct the 
human reductase cDNA was translationally fused at its N- 
terminus to the bacterial pelB leader sequence and expressed 
from the PtacPtac promoter of pCW; these expression levels 
were found to be approx. 40-fold higher than those obtained 
from the comparable construct lacking the pelB leader (data 
not shown). These results are consistent with the previously 
described high-level expression P450 reductases with ompA 
and pelB leader sequences [26,27]. A coexpression plasmid 
was constructed by subcloning the pelB-reductase cDNA 
into the optimised CYP3A4 expression plasmid NF14 [ll] 
as follows. pB215 was constructed by modification of NF14 
(see Section 2 and Fig. 1 for details). A fragment from pJR4 
containing the pelB-reductase cDNA and its PtacPtoc promoter 
was then subcloned into pB215, creating a plasmid, pB216, in 
which the two cDNAs, each bearing the P,,, Ptac promoter, 
were arranged head-to-tail (see Fig. 1). 
3.2. Coexpression of P450 reductase and CYP3A4 from pB216 
The culture conditions used were similar to those estab- 
lished to be optimal for expression of CYP3A4 from NF14 
[l 11, except that cultures were routinely supplemented with 6- 
aminolevulinic acid, as this was found to increase expression 
of CYP3A4. Similar observations have also been made by 
other workers for several P450 isoforms [19]. 
CYP3A4 content was determined in bacterial cells using 
Fe’+-CO vs. Fe’+ difference spectra. Typical spectra for whole 
cells containing pB216 and the control plasmids pCW, pJR4 
and NF14 are shown in Fig. 2A. For the assessment of cyto- 
chrome c reductase activities, bacterial membrane fractions 
were prepared since a high background cytochrome c reduc- 
tase activity was detected in whole cell or spheroplast prepara- 
tions (data not shown). The expression levels of P450 reduc- 
tase and CYP3A4 obtained are shown in Table 1. Table 1 
shows that the CYP3A4 yield measured in JM109 pB216 cells 
was typically 200 nmol/l culture and membranes contained 
215 pmol P450/mg protein. The P450 reductase activity was 
1315 nmol cytochrome c reduced/min per mg membrane pro- 
tein. 
A typical Western blot showing the recombinant proteins is 
shown in Fig. 2B. P450 reductase and CYP3A4 were detected 
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Fig. 1. Construction of pB216. pB216 was constructed by insertion 
of a pelB-reductase-containing fragment from pJR4 into the modi- 
fied NF14 construct, pB215. pB215 was constructed by replacement 
of the S&I-BgflI fragment of NF14 with an oligonucleotide contain- 
ing a transcription terminator (shown by a small arrow), thereby re- 
moving one of the two Bg/II restriction sites downstream of the 
CYP3A4 cDNA (step 1). The remaining BgLII site could then be 
used for subsequent cloning of the p&B-reductase cDNA from pJR4 
as a BclI-BgflI fragment without abolishing the transcription termi- 
nator of CYP3A4 expression (step 2). 
in the membrane fraction derived from pB216 (track 8), while 
P450 reductase alone and CYP3A4 alone were detected in 
those samples derived from pJR4 (track 6) and NF14 (track 
4) respectively. Some basal expression was observed in the 
absence of IPTG (tracks $7). However, the amounts of active 
P450 reductase and spectrally active CYP3A4 derived from 
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these fractions were very low compared to the induced cul- 
tures (data not shown). The specific contents of recombinant 
CYP3A4 and P450 reductase in JM109 pB216 membrane 
fractions appeared similar to those detected in a sample of 
human liver microsomes (tracks 8,9). 
3.3. Assays of CYP3A4 activity in whole cells and membranes 
JM109 pB216 cells were found to metabolise testosterone 
and nifedipine (Table 2). No 6P-hydroxytestosterone forma- 
tion was detected after incubation of testosterone with JM109 
pCW (vector only) or JM109 pJR4 (P450 reductase only) or 
JM109 NF14 (CYP3A4 only). Testosterone 6P-hydroxylase 
activity was still not detectable in these strains after increasing 
the incubation time of the assay from 5 min to 60 min. These 
data demonstrate that E. coli is unable to catalyse 6P-hydrox- 
ylation of testosterone in the presence of either CYP3A4 or 
P450 reductase alone. On coexpression of CYP3A4 with P450 
reductase, cells catalysed testosterone 6P-hydroxylation with a 
turnover rate of 17.3 min-‘. Similarly, membranes derived 
from JM109 pB216 cells catalysed the formation of 6P-hy- 
droxytestosterone with a turnover number of 25.5 min-‘. In 
the absence of Mg 2+, the activity was found to be approx. lo- 
fold lower (data not shown). Other reports have described 
turnover rates for this enzyme activity of N lo-12 min-’ 
using reconstituted systems containing bacterially expressed 
CYP3A4, P450 reductase and cytochrome b5 [11,18]. The 
turnover rate in human liver microsomes has been estimated 
to be 6 min-’ [28]. 
JM109 pB216 cells and membranes also catalysed oxidation 
of nifedipine (Table 2). The turnover number was typically 
15.2 min’ for cells and 12.7 min-’ for membranes. No ac- 
tivity was detected in cells expressing either P450 reductase or 
CYP3A4 alone. Membranes were also found to mediate me- 
tabolism of erythromycin in the presence of NADPH. The 
turnover number was typically 2.3 min-’ (Table 2). We 
were unable to measure this activity with intact cells, as the 
background release of formaldehyde from control cells in the 
absence in erythomycin was found to be too high (data not 
shown). 
4. Discussion 
We describe the generation of a functional P450 monooxy- 
genase system in E. coli, by coexpression of human CYP3A4 
and P450 reductase. To our knowledge this is the first instance 
Table 2 
CYP3A4-dependent metabolism of testosterone, nifedipine and erythromycin by JM109 pB216 cells and membranes 
Turnover (min-‘) 
Testosterone Nifedipine Erythromycina 
Cells Membranes Cells Membranes 
PCW <o .5 <o .5 <2 <2 <o .3 
NF14 <o .5 <o .5 <2 <2 <o .3 
pJR4 10 .5 <o .5 <2 <2 <o .3 
pB216 17.3 + 3.3 25.5 lt4.3 15.2 f 1.3 12.7 f 0.9 2.3 + 0.7 
Metabolism of three known CYP3A4 substrates by cells or membranes containing recombinant CYP3A4 and P450 reductase was assessed. 
Turnover numbers are recorded as nmol product formedlmin per nmol P450, and are shown fS.D. The products which were detected were 
6P_hydroxytestosterone, oxidised nifedipine and formaldehyde. Where no activities were detected, detection levels are shown. For testosterone 
metabolism, no 6P-hydroxytestosterone was formed even after 60 min incubation with cells or membranes lacking either CYP3A4 or P450 
reductase (data not shown). 
aFor erythromycin metabolism, activities could only be recorded with membranes, as the background level of formaldehyde formation by whole 
cells was very high. 
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Fig. 2. Expression of P450 reductase and CYP3A4 in E. coli. (A) 
Cytochrome P450 content was measured in whole bacterial cells 
(equivalent to 0.5 ml bacterial culture) by Fe’+-CO vs Fe2+ differ- 
ence spectra. (B) Levels of recombinant CYP3A4 and P450 reduc- 
tase in E. coli membranes determined by Western blotting. JM109 
cells were transformed with pCW (control plasmid), NF14 
(CYP3A4 only), pJR4 (P450 reductase only) or pB216 (CYP3A4/ 
P450 reductase coexpression). Tracks were loaded alternately with 
membrane samples derived from cultures which had been uninduced 
(lanes 1,3,5,7) or induced (lanes 2,4,6,8) with IPTG. Lanes 1,2 con- 
tained membranes from JM109 pCW cells, lanes 3,4 from JM109 
NF14 cells, lanes 5,6 from JM109 pJR4 cells, and lanes 7,8 from 
JM109 pB216 cells. Track 9 contains human liver microsomal pro- 
tein. All lanes were loaded with 10 wg membrane protein. Recombi- 
nant CYP3A4 and P450 reductase were detected using a combina- 
tion of anti-CYP3A and anti-P450 reductase antibodies. 
in which a mammalian xenobiotic-metabolising P450 has been 
shown to be significantly catalytically active in intact E. coli. 
The yields of recombinant proteins were high: 215 pmol P4501 
mg protein, and a reductase activity of 1315 nmol cytochrome 
c reduced/min per mg were obtained. These levels are signifi- 
cantly higher than those of CYP3A4 and P450 reductase 
measured in human liver microsomes (90 pmol/mg protein 
and 230 nmol cytochrome c reduced/min per mg protein re- 
spectively [29,30]). The yield of P450 achieved in this strain is 
approx. 200-fold higher than that achieved in a strain coex- 
pressing CYP2El and P450 reductase [20]. 
JM109 pB216 cells catalysed CYP3A4-mediated reactions, 
indicating that electron transfer occurred efficiently in vivo. 
This was exemplified by turnover numbers which were in ex- 
cess of those estimated in human liver. Activities measured 
towards the substrates we tested were found to be comparable 
to those obtained by other workers using purified recombi- 
nant CYP3A4 in reconstituted systems [11,19]. The reconsti- 
tuted systems described contained components other than 
those included here, such as detergent, an optimised phospho- 
lipid mixture, glutathione, and cytochrome bg, in order to 
obtain maximal CYP3A4 activity towards testosterone and 
nifedipine [ 11,18,28]. It was therefore extremely interesting 
that, in our studies, high levels of CYP3A4 activity towards 
these substrates were observed in the absence of exogenously 
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added cytochrome bs. It has been postulated that cytochrome 
b5 binds to CYP3A4 in the presence of P450 reductase, sub- 
strate and divalent cations such as Mg2+ to facilitate reduc- 
tion by P450 reductase thereby increasing the rate of P450- 
mediated metabolism of certain substrates [18,28]. We found 
that while the testosterone 6P-hydroxylase activity of mem- 
branes containing CYP3A4 and P450 reductase was increased 
lo-fold by Mg2+, the nifedipine oxidase activity was already 
high and was not significantly affected by the addition of 
Mg2+. In addition, the enzyme activities towards both of these 
substrates were not stimulated by Mg2+ when assayed in in- 
tact cells, perhaps due to high intracellular pools of divalent 
cations. Taken together, these results suggest that there is an 
endogenous bacterial protein which can substitute for cyto- 
chrome b5 to stimulate CYP3A4 activity, but that, if this is 
the case, the complex formed between this protein, P450 re- 
ductase and CYP3A4 has different substrate-specific require- 
ments for Mg2+ ions than the complex involving cytochrome 
bg. In future experiments we will address this issue by coex- 
pression of cytochrome bs together with CYP3A4 and P450 
reductase in E. coli. 
In summary, we have successfully achieved high level coex- 
pression of CYP3A4 and P450 reductase in E. coli. The re- 
sulting cells and membranes derived from them are proficient 
for metabolism of several known CYP3A4 substrates. The 
specific activities achieved from our coexpression strain com- 
pare favourably to results previously obtained with complex 
reconstituted systems. This approach will be used as a model 
system for future coexpression of further P450 isoforms with 
P450 reductase in E. coli, and we expect that it will signifi- 
cantly aid the use of cytochrome P45Os in biocatalysis and in 
drug development. 
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